Fracture risk assessment by the FRAX model

References

• Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467–475.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: World Health Organization; 1994.
   Google Scholar
• Kanis JA, on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. Sheffield: WHO Collaborating Centre, University of Sheffield, UK; 2008.
   Google Scholar
• Kanis JA, Johansson H, Harvey NC, et al. A brief history of FRAX. Arch Osteoporos. 2018;13(1):118.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397.
   PubMed Web of Science ®Google Scholar
• Nguyen ND, Frost SA, Center JR, et al. Development of a nomogram for individualizing hip fracture risk in men and women. Osteoporos Int. 2007;18(8):1109–1117.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ. 2012;344:e3427.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QfractureScores. BMJ. 2009;339:b4229.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239–2256.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Chalhoub D, Kassem AM, et al. Geographic and ethnic disparities in osteoporotic fractures. Nat Rev Endocrinol. 2014;10(6):338–351.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. Worldwide uptake of FRAX. Arch Osteoporos. 2014;9:166.
   PubMed Web of Science ®Google Scholar
• Chotiyarnwong P, Harvey NC, Johansson H, et al. Temporal changes in access to FRAXI in Thailand between 2010 and 2018. Arch Osteoporos. 2019;14(1):66.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Harvey NC, Johansson H, et al. Global impact of COVID-19 on non-communicable disease management: descriptive analysis of access to FRAX fracture risk online tool for prevention of osteoporotic fractures. Osteoporos Int. 2021;32(1):39–46.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18(8):1033–1046.
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695–1705.
   PubMedGoogle Scholar
• Johansson H, Oden A, Johnell O, et al. Optimization of BMD measurements to identify high risk groups for treatment–a test analysis. J Bone Miner Res. 2004;19(6):906–913.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Morin S, Lix LM, et al. Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int. 2012;23(1):75–85.
   PubMed Web of Science ®Google Scholar
• Hoff M, Meyer HE, Skurtveit S, et al. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporos Int. 2017;28(10):2935–2944.
   PubMed Web of Science ®Google Scholar
• Goldshtein I, Gerber Y, Ish-Shalom S, et al. Fracture risk assessment with FRAX using real-world data in a population-based cohort from Israel. Am J Epidemiol. 2018;187(1):94–102.
   PubMed Web of Science ®Google Scholar
• Dagan N, Cohen-Stavi C, Leventer-Roberts M, et al. External validation and comparison of three prediction tools for risk of osteoporotic fractures using data from population based electronic health records: retrospective cohort study. BMJ. 2017;356:i6755.
   PubMedGoogle Scholar
• Fraser LA, Langsetmo L, Berger C, et al. Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int. 2011;22(3):829–837.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Lix LM, Johansson H, et al. Independent clinical validation of a Canadian FRAX tool: fracture prediction and model calibration. J Bone Miner Res. 2010;25(11):2350–2358.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Cooper C, et al. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinic’an's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.
   PubMed Web of Science ®Google Scholar
• Orimo H, Nakamura T, Hosoi T, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis-executive summary. Arch Osteoporos. 2012;7(1):3–20.
   PubMedGoogle Scholar
• Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19(4):437–447.
   PubMed Web of Science ®Google Scholar
• Nelson HD, Haney EM, Chou R, et al. Screening for osteoporosis: systematic review to update the 2002 U.S. preventive services task force recommendation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010. (Report No.: 10-05145-EF-1).
   Google Scholar
• US Preventive Services Task Force. Screening for osteoporosis to prevent fractures. US preventive services task force recommendation statement. JAMA. 2018;319(24):2521–2531.
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). Management of osteoporosis and the prevention of fragility fractures. Edinburgh: SIGN; 2015 [March 2015; Updated 2021]. https://www.sign.ac.uk/media/1812/sign-142-osteoporosis-v3.pdf). (SIGN publication no 142).
   Google Scholar
• Kanis JA, McCloskey EV, Harvey NC, et al. Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res. 2015;30(10):1747–1753.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int. 2005;16(3):229–238.
   PubMed Web of Science ®Google Scholar
• Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009;62(2):105–108.
   PubMed Web of Science ®Google Scholar
• Lekamwasam S, Adachi JD, Agnusdei D, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257–2276.
   PubMed Web of Science ®Google Scholar
• Clark P, Denova-Gutierrez E, Zerbini C, et al. FRAX-based intervention and assessment thresholds in seven Latin American countries. Osteoporos Int. 2018;29(3):707–715.
   PubMed Web of Science ®Google Scholar
• McCloskey E, Kanis JA, Johansson H, et al. FRAX-based assessment and intervention thresholds-an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int. 2015;26(8):2091–2099.
   PubMed Web of Science ®Google Scholar
• Body JJ, Marin F, Kendler DL, et al. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial. Osteoporos Int. 2020;31(10):1935–1942.
   PubMed Web of Science ®Google Scholar
• Geusens P, Marin F, Kendler DL, et al. Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO Trial. J Bone Miner Res. 2018;33(5):783–794.
   PubMed Web of Science ®Google Scholar
• Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–240.
   PubMed Web of Science ®Google Scholar
• Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Harvey NC, et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines. Osteoporos Int. 2021. DOI:https://doi.org/10.1007/s00198-021-05942-2
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. London: CHMP; 2006.
   Google Scholar
• McCloskey EV, Johansson H, Oden A, et al. The effect of abaloparatide-SC on fracture risk is independent of baseline FRAX fracture probability: a post hoc analysis of the ACTIVE Study. J Bone Miner Res. 2017;32(8):1625–1631.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Fitzpatrick LA, Hu MY, et al. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos. 2019;14(1):15.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone. 2010;47(4):729–735.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44(6):1049–1054.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int. 2009;20(5):811–817.
   PubMed Web of Science ®Google Scholar
• Harvey NC, Kanis JA, Oden A, et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX. Osteoporos Int. 2015;26(9):2347–2353.
   PubMed Web of Science ®Google Scholar
• Harvey NC, Kanis JA, Oden A, et al. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture. Osteoporos Int. 2015;26(11):2677–2684.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res. 2012;27(7):1480–1486.
   PubMed Web of Science ®Google Scholar
• Donaldson MG, Palermo L, Ensrud KE, et al. Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial. J Bone Miner Res. 2012;27(8):1804–1810.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®. Osteoporos Int. 2011;22(8):2347–2355.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Johansson H, Harvey NC, et al. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporos Int. 2021. DOI:https://doi.org/10.1007/s00198-020-05815-0
   Google Scholar
• Kanis JA, Cooper C, Rizzoli R, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44.
   PubMed Web of Science ®Google Scholar
• Shepstone L, Lenaghan E, Cooper C, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741–747.
   PubMed Web of Science ®Google Scholar
• Rubin KH, Rothmann MJ, Holmberg T, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int. 2018;29(3):567–578.
   PubMed Web of Science ®Google Scholar
• Merlijn T, Swart KM, van Schoor NM, et al. The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res. 2019;34(11):1993–2000.
   PubMed Web of Science ®Google Scholar
• Merlijn T, Swart KMA, van der Horst HE, et al. Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int. 2020;31(2):251–257.
   PubMed Web of Science ®Google Scholar
• Soreskog E, Borgstrom F, Shepstone L, et al. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporos Int. 2020;31(8):1499–1506.
   PubMed Web of Science ®Google Scholar
• Turner DA, Khioe RFS, Shepstone L, et al. The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP Study. J Bone Miner Res. 2018;33(5):845–851.
   PubMed Web of Science ®Google Scholar
• Kanis JA, McCloskey E, Johansson H, et al. FRAX(®) with and without bone mineral density. Calcif Tissue Int. 2012;90(1):1–13.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Lix LM, Johansson HO, et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res. 2012;27(6):1243–1251.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–816.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Lix LM, Johansson H, et al. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int. 2011;22(3):839–847.
   PubMed Web of Science ®Google Scholar
• Johansson H, Kanis JA, Oden A, et al. Impact of femoral neck and lumbar spine BMD discordances on FRAX probabilities in women: a meta-analysis of international cohorts. Calcif Tissue Int. 2014;95(5):428–435.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Oden A, Harvey NC, et al. Adjusting fracture probability by trabecular bone score. Calcif Tissue Int. 2015;96(6):500–509.
   PubMed Web of Science ®Google Scholar
• McCloskey EV, Oden A, Harvey NC, et al. A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res. 2016;31(5):940–948.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Lix LM, Morin SN, et al. Adjusting hip fracture probability in men and women using hip axis length: the Manitoba Bone Density Database. J Clin Densitom. 2016;19(3):326–331.
   PubMed Web of Science ®Google Scholar
• Masud T, Binkley N, Boonen S, et al. Official positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®). J Clin Densitom. 2011;14(3):194–204.
   PubMed Web of Science ®Google Scholar
• Leslie WD, Johansson H, McCloskey EV, et al. Comparison of methods for improving fracture risk assessment in diabetes: the Manitoba BMD registry. J Bone Miner Res. 2018;33(11):1923–1930.
   PubMed Web of Science ®Google Scholar
• Johansson H, Oden A, Lorentzon M, et al. Is the Swedish FRAX model appropriate for Swedish immigrants? Osteoporos Int. 2015;26(11):2617–2622.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Harvey NC, et al. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int. 2020;31(10):1817–1828.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Johansson H, et al. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 2020;32(2):187–196.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Harvey NC, Johansson H, Odén A, Leslie WD, McCloskey EV. FRAX update. J Clin Densitometry. 2017;20:360–367.
   PubMed Web of Science ®Google Scholar